BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and they could deliver an Omicron-based vaccine in March 2022 if needed.In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralizing antibodies but that a third dose of their vaccine increased the neutralizing antibodies by a factor of 25.Blood obtained from people that had their third booster shot a month ago neutralized the Omicron variant about as effectively as blood after two doses fought off the original virus first identified in.